2 Dec 2024 15:05
2 December 2024 15:05 GMT
Β
Β
BLOCK LISTING SIX MONTHLY RETURN
Β
Information provided on this form must be typed or printed electronically and provided to an ris.
Β
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Β
Date: 2 December 2024
Β
Name of applicant: | ASTRAZENECA PLC | |||
Name of scheme: | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME | |||
Period of return: | From: | 1 JUNE 2024 | To: | 30 NOVEMBER 2024 |
Balance of unallotted securities under scheme(s) from previous return: | 4,090,043 | |||
Plus:Β The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
Less:Β Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 60,887 | |||
Equals:Β Balance under scheme(s) not yet issued/allotted at end of period: | 4,029,156 | |||
Β
Name of contact: | Hannah Tattersall |
Telephone number of contact: | +44 (0)20 3749 5000 |
Β
Β
AstraZenecaΒ
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.comβ―and follow the Company on social mediaβ―@AstraZenecaΒ
Β
Β
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Β
Β
Adrian KempCompany Secretary
AstraZeneca PLC
Β
Follow the stocks